ArticleTransfusion2026
Development and production of allogeneic cord blood-derived red blood cell concentrates for transfusion to extremely preterm neonates, the All-Cord study.
Article in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cord blood red cell concentrates for preterm neonate transfusion: Insights from the multicenter BORN trial.Transfusion · 2026Article
- From Donation to Innovation: New Blood-Derived Products.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtremely preterm neonates often require red blood cell (RBC) transfusions derived from adult donors. These transfusions introduce adult hemoglobin into a neonatal hematopoietic system dominated by fetal hemoglobin (HbF), shifting the oxygen-dissociation curve and increasing oxygen delivery to immature tissues. This contributes to oxidative stress and has been associated with prematurity-related diseases. Cord blood (CB)-derived red cell concentrates (CB-RCCs) offer a new physiological alternative by preserving HbF. To enable clinical implementation, CB-RCCs must meet (inter)national quality standards. This study investigated the impact of pre-filtration dilution, storage in non-di(2-ethylhexyl)phthalate (DEHP) plasticized bags, and three additive solutions-saline-adenine-glucose-mannitol (SAGM), phosphate-adenine-glucose-guanosine-saline-mannitol (PAGGSM), and SOL-X-on CB-RCC quality over 21 days. STUDY DESIGN AND
methodsCB was collected after term delivery and processed within 24 h into leukocyte- and platelet-depleted CB-RCCs. Products, either pre-filtration diluted or undiluted, were stored up to 21 days in 1,2-cyclohexane dicarboxylic acid diisononyl ester- or DEHP-plasticized polyvinyl chloride bags containing SAGM, PAGGSM, or SOL-X additive solutions. Quality parameters were assessed on Days 1, 7, 14, and 21. Quality standards were compared against (inter)national requirements for adult RCC.
resultsPre-filtration dilution to maximize yield was found to impair product quality. CB-RCCs stored in non-DEHP bags with PAGGSM showed the lowest hemolysis at Day 21 (0.30 ± 0.09%), outperforming SAGM (0.57 ± 0.16%). Red blood cells in non-DEHP bags also preserved adenosine triphosphate levels and deformability better than in DEHP bags. DISCUSSION: We demonstrated that CB-RCCs stored in non-DEHP bags with PAGGSM as an additive solution meet (inter)national Blood Bank quality standards up to 21 days of in vitro storage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.